These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26188320)

  • 1. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
    Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
    Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
    Even MP; Young K; Winter G; Hook S; Engert J
    Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
    Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
    Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part I: Physicochemical characterisation.
    Myschik J; Eberhardt F; Rades T; Hook S
    J Drug Target; 2008 Apr; 16(3):213-23. PubMed ID: 18365883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
    Myschik J; McBurney WT; Rades T; Hook S
    Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
    Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
    J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into process understanding of solid lipid extrusion (SLE) of extruded lipid implants for sustained protein delivery.
    Vollrath M; Engert J; Winter G
    Eur J Pharm Biopharm; 2018 Sep; 130():11-21. PubMed ID: 29913270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
    Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
    Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants.
    Sax G; Winter G
    J Control Release; 2012 Oct; 163(2):187-94. PubMed ID: 22964391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants.
    Vollrath M; Engert J; Winter G
    Eur J Pharm Biopharm; 2017 Aug; 117():244-255. PubMed ID: 28442372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of change of matrix crystallinity and polymorphism on ovalbumin release from lipid-based implants.
    Duque L; Körber M; Bodmeier R
    Eur J Pharm Sci; 2018 May; 117():128-137. PubMed ID: 29452211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles.
    Moreno JAS; Panou DA; Stephansen K; Chronakis IS; Boisen A; Mendes AC; Nielsen LH
    AAPS PharmSciTech; 2018 Nov; 19(8):3770-3777. PubMed ID: 30280354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
    Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
    J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep.
    Walduck AK; Opdebeeck JP; Benson HE; Prankerd R
    J Control Release; 1998 Feb; 51(2-3):269-80. PubMed ID: 9685925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/spheronization and an investigation of their stability.
    Yan X; He H; Meng J; Zhang C; Hong M; Tang X
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1221-9. PubMed ID: 22713120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method.
    Demana PH; Davies NM; Berger B; Rades T
    Int J Pharm; 2004 Jul; 278(2):263-74. PubMed ID: 15196631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection.
    Bobbala S; McDowell A; Hook S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 975():45-51. PubMed ID: 25438242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure.
    Schwab M; McGoverin CM; Gordon KC; Winter G; Rades T; Myschik J; Strachan CJ
    Eur J Pharm Biopharm; 2013 Aug; 84(3):456-63. PubMed ID: 23385286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twin-screw extrusion of sustained-release oral dosage forms and medical implants.
    Feng X; Zhang F
    Drug Deliv Transl Res; 2018 Dec; 8(6):1694-1713. PubMed ID: 29235074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Quil A on liposomal membranes.
    Paepenmüller T; Müller-Goymann CC
    Int J Pharm; 2014 Nov; 475(1-2):138-46. PubMed ID: 25107288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.